Bruker Corporation 2023 JP Morgan Healthcare Conference
YTD Q3 2022 FINANCIALS AND FY2023
YTD Q3 2022: Robust Organic Growth with Solid Margin Expansion
Solid Q4 2022 Organic Revenue Growth, Strong 2023 Outlook
YTD Q3 2022 Financials (all year-over-year)
Revenue increased $87.9M, up +5.1%
Organic revenue growth +10.7% (BSI +9.9%, BEST +18.7%);
acquisitions tailwind +1.3%, FX headwind -6.9%
* Non-GAAP gross margin 52.6%, up +160 bps
* Non-GAAP operating margin 19.6%, up +80 bps
Continuing significant investments in PA 2.0 R&D, M&S opex
Non-GAAP EPS of $1.60, up 6%
Revenues [$M]
1,822.3
2023 Bruker
1,734.4
YTD
Q3-21
YTD
Q3-22
Non-GAAP EPS
$1.51
$1.60
-
E
I I
Q4 2022 Preliminary Revenue Estimate and FY 2023 Outlook(1)
Q4-22 preliminary revenue estimate: mid-to-high single digit %
organic growth YoY2; reported revenue above consensus
ā Solid demand, with Q4-22 BSI book-to-bill expected at >1
ā BSI backlog remains high due to supply chain constraints
Preliminary 2023 outlook: mid-to-high single digit % organic revenue
growth YoY
Project Accelerate 2.0 initiatives performing well, Proteomics
and Spatial Biology accelerating organically and inorganically
BSI Geographic Mix
(YTD 3Q 2022
revenue)
YTD Q3-22
YTD Q3-21
(1) Please see disclosures on slide 21 (2) Q4-22 preliminary: GAAP revenue up low single digits % YoY:
organic revenue up mid-to-high single digit %, ~7% headwind from FX, ~1.5% tailwind from acquisitions.
32%
33% {
31%
BRUKER
ROW: 4%
2023 JP Morgan Healthcare Conference |
January 9, 2023
IView entire presentation